Oriola Oyj operates within the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Oriola Oyj with three other
drug stores in Europe:
Selcuk Ecza Deposu Ticaret ve Sanayi AS
sales of 10.69 billion Turkish Liras [US$2.60 billion]
of which 100%
was Medical and Hospital Equipment),
Udg Healthcare Plc
(1.10 billion Euro [US$1.34 billion]
of which 67%
was Ashfield), and
based in Poland
(7.49 billion Polish New Zlotys [US$2.17 billion]
of which 99%
was Pharmaceutical Wholesale).
During the year ended December of 2017, sales at
Oriola Oyj were 1.53 billion Euro (US$1.87 billion).
decrease of 7.0%
versus 2016, when the company's sales were 1.64 billion Euro.
Contributing to the drop in overall sales was the 3.8% decline
in Consumer, from 811.50 million Euro to 780.30 million Euro.
There were also decreases in sales in
Services (down 3.4% to 2.48 billion Euro)
However, these declines were partially offset by the increase in sales of
Healthcare (up 95.9% to 71.10 million Euro)